References
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
- Hamers PAH, Elferink MAG, Stellato RK, et al. Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data. Int J Cancer. 2021;148(2):296–306. DOI:https://doi.org/10.1002/ijc.33200.
- André T, Shiu -K-K, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–2218. DOI:https://doi.org/10.1056/NEJMoa2017699.
- Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E–mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol. 2021 Feb 1:39(4):273–284. DOI:https://doi.org/10.1200/JCO.20.02088.
- Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015 Nov;21(11):1350–1356. DOI:https://doi.org/10.1038/nm.3967.
- Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004 Oct;351(17):1731–1740. DOI:https://doi.org/10.1056/NEJMoa040694.
- Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 May;393(10184):1948–1957. (London, England). DOI:https://doi.org/10.1016/S0140-6736(18)32557-1
- Girling DJ, Bancewicz J, Clark PI, et al. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002 May;359(9319):1727–1733. (London, England).
- Gosavi R, Chia C, Michael M, et al. Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2021 Oct;36(10):2063–2070.
- Karoui M, Rullier A, Piessen G, et al. Perioperative FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a phase II multicenter randomized controlled trial (PRODIGE 22). Ann Surg. 2020 Apr;271(4):637–645. DOI:https://doi.org/10.1097/SLA.0000000000003454.
- Agbamu DA, Day N, Walsh CJ, et al. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012 Nov;13(11):1152–1160. DOI:https://doi.org/10.1016/S1470-2045(12)70348-0.
- Arredondo J, Baixauli J, Pastor C, et al. Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery. Clin Transl Oncol. 2017 Mar;19(3):379–385. DOI:https://doi.org/10.1007/s12094-016-1539-4.
- Arredondo J, González I, Baixauli J, et al. Tumor response assessment in locally advanced colon cancer after neoadjuvant chemotherapy. J Gastrointest Oncol. 2014;5(2):104–111. DOI:https://doi.org/10.3978/j.issn.2078-6891.2014.006.
- Jakobsen A, Andersen F, Fischer A, et al. Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. Acta Oncol. 2015 Nov;54(10):1747–1753. DOI:https://doi.org/10.3109/0284186X.2015.1037007.
- Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018 Oct;24(11):1655–1661. DOI:https://doi.org/10.1038/s41591-018-0198-0.
- Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018 May;378(21):1976. DOI:https://doi.org/10.1056/NEJMoa1716078.
- Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019 Nov;25(11):1706–1714. DOI:https://doi.org/10.1038/s41591-019-0628-7.
- Blank CU, Haanen JB, Ribas A, et al. CANCER IMMUNOLOGY. The “cancer immunogram.” Science. 2016 May;352(6286):658–660.
- Mlecnik B, Bindea G, Angell HK, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016 Mar;44(3):698–711. DOI:https://doi.org/10.1016/j.immuni.2016.02.025.
- Maby P, Tougeron D, Hamieh M, et al. Correlation between density of CD8+ T-cell infiltrate in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. Cancer Res. 2015 Sep;75(17):3446–3455. DOI:https://doi.org/10.1158/0008-5472.CAN-14-3051.
- Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020 Apr;26(4):566–576. DOI:https://doi.org/10.1038/s41591-020-0805-8.
- Lau D, Kalaitzaki E, Church DN, et al. Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. ESMO open. 2020 Feb;5(1):e000638. DOI:https://doi.org/10.1136/esmoopen-2019-000638.
- Sinicrope FA, Ou F-S, Shi Q, Nixon AB, Mody K, and Levasseur Aet al, Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502). J Clin Oncol. 2017;35(15_suppl):TPS3630–TPS3630.
- Argilés G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. Official Journal of the European Society for Medical Oncology. England. 2020;31(10):1291–1305. DOI:https://doi.org/10.1016/j.annonc.2020.06.022.
- Galon J. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006 Sep 29;313(5795):1960–1964. DOI:https://doi.org/10.1126/science.1129139.
- Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005 Dec 22:353(25):2654–2666. DOI:https://doi.org/10.1056/NEJMoa051424.
- Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008 Sep;14(9):985–990. DOI:https://doi.org/10.1038/nm.1789.
- Tarazona N, Gimeno-Valiente F, Gambardella V, Zuñiga S, Rentero-Garrido P, and Huerta Met al, Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol. 2019;30(11):1804–1812.
- Tie J, Cohen JD, Wang Y, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 2019 Dec;5(12):1710–1717. DOI:https://doi.org/10.1001/jamaoncol.2019.3616.
- Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019 Aug;5(8):1124–1131. DOI:https://doi.org/10.1001/jamaoncol.2019.0528.
- Masfarré L, Vidal J, Fernández-Rodríguez C, et al. ctDNA to guide adjuvant therapy in localized colorectal cancer (CRC). Cancers (Basel). 2021 Jun;13(12):2869.
- Weiss J, Yaeger RD, Johnson ML, et al. COLORECTAL CANCER LBA6 KRYSTAL-1: adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. Ann Oncol. 2021;32:S1294.
- Sunakawa Y, Sakamoto Y, Inoue E, et al. LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer. Ann Oncol. 2020 Jul;31:S242–3.
- Diaz L, Marabelle A, Kim TW, et al. Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers. Ann Oncol. 2017 Sep;28:v128–9.
- Pietrantonio F, Morano F, Lonardi S, et al. 383O MAYA trial: temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC). Ann Oncol. 2021 Sep;32:S530–1.
- Prior IA, Lewis PD, Mattos C. A comprehensive survey of ras mutations in cancer. Cancer Research. 2012;72(10):2457–2468.
- Yokota T. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem. 2012;12(2):163–171.
- Schirripa M, Cremolini C, Loupakis F, et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer. 2015;136(1):83–90. DOI:https://doi.org/10.1002/ijc.28955.
- Douillard J-Y, Oliner KS, Siena S, et al. Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013 Sep;369(11):1023–1034. DOI:https://doi.org/10.1056/NEJMoa1305275.
- Van Cutsem E, Lenz H-J, Köhne C-H, Heinemann V, Tejpar S, and Melezínek Iet al, Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer. J Clin Oncol. 2015;33(7):692–700.
- Bokemeyer C, Köhne C-H, Ciardiello F, Lenz H-J, Heinemann V, and Klinkhardt Uet al, FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer. 2015;51(10):1243–52.
- Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016 Aug;27(8):1386–1422. DOI:https://doi.org/10.1093/annonc/mdw235.
- Van Cutsem E, Lenz H-J, Köhne C-H, et al. Fluorouracil, Leucovorin, and Irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015 Mar;33(7):692–700. DOI:https://doi.org/10.1200/JCO.2014.59.4812.
- Santos C, Azuara D, Viéitez JM, et al. Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. Ann Oncol. 2019 May 1:30(5):796–803. DOI:https://doi.org/10.1093/annonc/mdz082.
- Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015 Jul 1;21(7):795–801.
- Hutter C, Zenklusen JC. The cancer genome atlas: creating lasting value beyond its data. Cell. 2018 Apr;173(2):283–285.
- Hong DS, Fakih MG, Strickler JH, et al. KRAS G12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020 Sep 24:383(13):1207–1217. DOI:https://doi.org/10.1056/NEJMoa1917239.
- Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRAS G12C inhibition in cancer. N Engl J Med. 2021 Jun;384(25):2382–2393. DOI:https://doi.org/10.1056/NEJMoa2105281.
- Amodio V, Yaeger R, Arcella P, et al. EGFR blockade reverts resistance to KRAS g12c inhibition in colorectal cancer. Cancer Discov. 2020 Aug;10(8):1129–1139. DOI:https://doi.org/10.1158/2159-8290.CD-20-0187.
- Tanaka N, Lin JJ, Li C, et al. Clinical acquired resistance to KRAS G12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS–MAPK reactivation. Cancer Discov. 2021 Apr 6:11(8):1913–1922. DOI:https://doi.org/10.1158/2159-8290.CD-21-0365.
- Weiss J, Yaegar RD, Johnson ML, et al. KRYSTAL-1: adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. Ann Oncol. 2021;32:S1294. European S. DOI:https://doi.org/10.1016/j.annonc.2021.08.2093.
- Seligmann JF, Fisher DJ, Brown LC, et al. Inhibition of WEE1 Is Effective in TP53 - and RAS -mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) With active monitoring. J Clin Oncol. 2021 Nov 20:39(33):3705–3715. DOI:https://doi.org/10.1200/JCO.21.01435.
- Cantwell-Dorris ER, O’Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011;10(3):385–394.
- Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009;101(4):715–721. DOI:https://doi.org/10.1038/sj.bjc.6605177.
- Tie J, Gibbs P, Lipton L, et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAFV600E mutation. Int J Cancer. 2011 May 1:128(9):2075–2084. DOI:https://doi.org/10.1002/ijc.25555.
- Gonsalves WI, Mahoney MR, Sargent DJ, et al. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 2014;106(7):1–8. DOI:https://doi.org/10.1093/jnci/dju106.
- Clancy C, Burke JP, Kalady MF, et al. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Color Dis. 2013 Dec;15(12):e711–8.
- Ogino S, Brahmandam M, Cantor M, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol. 2006;19(1):59–68. DOI:https://doi.org/10.1038/modpathol.3800482.
- Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the Cairo, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20(20):5322–5330. DOI:https://doi.org/10.1158/1078-0432.CCR-14-0332.
- Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306–1315. DOI:https://doi.org/10.1016/S1470-2045(15)00122-9.
- Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–3506. DOI:https://doi.org/10.1200/JCO.2012.42.8201.
- Cremolini C, Antoniotti C, Stein A, et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol. 2020 Aug 20; 38(28):3314–3324. JCO.20.01225. DOI:https://doi.org/10.1200/JCO.20.01225.
- Hyman DM, Diamond EL, Baselga J, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726–736. DOI:https://doi.org/10.1056/NEJMoa1502309.
- Kopetz S, Desai J, Chan E, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol. 2015;33(34):4032–4038. DOI:https://doi.org/10.1200/JCO.2015.63.2497.
- Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012 Mar 26:483(7387):100–103. DOI:https://doi.org/10.1038/nature10868.
- Kopetz S, Guthrie KA, Morris VK, et al. Randomized trial of irinotecan and cetuximab with or without Vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). J Clin Oncol. 2021 Feb 1:39(4):285–294. DOI:https://doi.org/10.1200/JCO.20.01994.
- Yaeger R, Cercek A, O’Reilly EM, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res. 2015;21(6):1313–1320. DOI:https://doi.org/10.1158/1078-0432.CCR-14-2779.
- Corcoran RB, Atreya CE, Falchook GS, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol. 2015;33(34):4023–4031. DOI:https://doi.org/10.1200/JCO.2015.63.2471.
- Corcoran RB, Dias-Santagata D, Bergethon K, et al., BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal. 2010 Nov 23;3(149):ra84–ra84. DOI:https://doi.org/10.1126/scisignal.2001148.
- Van Geel RMJM, Tabernero J, Elez E, et al. A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer. Cancer Discov. 2017;7(6):610–619. DOI:https://doi.org/10.1158/2159-8290.CD-16-0795.
- Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, and Yoshino Tet al, Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer. N Engl J Med. 2019;381(17):1632–43.
- Grothey A, Tabernero J, Taieb J, et al. LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer. Ann Oncol. 2020 Jul;31(S3):S242–3. DOI:https://doi.org/10.1016/j.annonc.2020.04.080.
- Ros J, Baraibar I, Sardo E, et al. BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer. Ther Adv Med Oncol. 2021 Jan;13:175883592199297.
- Élez E, Ros J, Martini G, et al. LBA-3 Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR ± MEK inhibitors. Ann Oncol. 2021 Jul;32:S226–7.
- Corcoran R, Giannakis M, Allen J, et al. SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients. Ann Oncol. 2020 Jul;31(226–227):S226–7. DOI:https://doi.org/10.1016/j.annonc.2020.04.041.
- Ross JS, Fakih M, Ali SM, et al. Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 2018;124(7):1358–1373. DOI:https://doi.org/10.1002/cncr.31125.
- Valtorta E, Martino C, Sartore-Bianchi A, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015;28(11):1481–1491. DOI:https://doi.org/10.1038/modpathol.2015.98.
- Loree JM, Bailey AM, Johnson AM, et al. Molecular landscape of ERBB2/ERBB3 mutated colorectal cancer. JNCI J Natl Cancer Inst. 2018 Dec 1:110(12):1409–1417. DOI:https://doi.org/10.1093/jnci/djy067.
- Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient- derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1(6):508–523. DOI:https://doi.org/10.1158/2159-8290.CD-11-0109.
- Bregni G, Sciallero S, Sobrero A. HER2 amplification and anti-EGFR sensitivity in advanced colorectal cancer. JAMA Oncol. 2019 May 1;5(5):605.
- Raghav KPS, Overman MJ, Yu R, et al. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol. 2016 May 20:34(15_suppl):3517. DOI:https://doi.org/10.1200/JCO.2016.34.15_suppl.3517.
- Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738–746. DOI:https://doi.org/10.1016/S1470-2045(16)00150-9.
- Siravegna G, Sartore-Bianchi A, Nagy RJ, et al. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin Cancer Res. 2019;25(10):3046–3053. DOI:https://doi.org/10.1158/1078-0432.CCR-18-3389.
- Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from mypathway, an open-label, phase IIA multiple basket study. J Clin Oncol. 2018;36(6):536–542. DOI:https://doi.org/10.1200/JCO.2017.75.3780.
- Nakamura Y, Okamoto W, Kato T, et al. TRIUMPH: primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): a GOZILA sub-study. Ann Oncol. 2019 Oct;30:v199–200.
- Strickler JH, Zemla T, Ou F-S, et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): initial results from the MOUNTAINEER trial. Ann Oncol. 2019 Oct;30:v200.
- Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):779–789. DOI:https://doi.org/10.1016/S1470-2045(21)00086-3.
- Lynch HT, Snyder CL, Shaw TG, et al. Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer. 2015 Mar;15(3):181–194.
- Ma J, Setton J, Lee NY, et al. The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. Nat Commun. 2018 Dec;9(1):3292.
- Fang M, Ou J, Hutchinson L, et al. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype. Mol Cell. 2014 Sep;55(6):904–915.
- Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002 Feb;20(4):1043–1048. DOI:https://doi.org/10.1200/JCO.2002.20.4.1043.
- Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005 Jan;23(3):609–618.
- Mohan HM, Ryan E, Balasubramanian I, et al. Microsatellite instability is associated with reduced disease specific survival in stage III colon cancer. Eur J Surg Oncol. 2016 Nov;42(11):1680–1686. DOI:https://doi.org/10.1016/j.ejso.2016.05.013.
- Smyrk TC, Watson P, Kaul K, et al. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001 Jun;91(12):2417–2422.
- Marcus L, Lemery SJ, Keegan P, et al. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019 Jul;25(13):3753–3758.
- Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 Jul;357(6349):409–413. DOI:https://doi.org/10.1126/science.aan6733.
- Andre T, Lonardi S, Wong M, et al. Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): first report of the full cohort from CheckMate-142. J Clin Oncol. 2018 Feb;36(4_suppl):553. DOI:https://doi.org/10.1200/JCO.2018.36.4_suppl.553.
- Andre T, Shiu -K-K, Kim TW, et al. Final overall survival for the phase III KN177 study: pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). J Clin Oncol. 2021 May 20:39(15_suppl):3500. DOI:https://doi.org/10.1200/JCO.2021.39.15_suppl.3500.
- Russell JP, Powell DJ, Cunnane M, et al. The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. Oncogene. 2000 Nov;19(50):5729–5735. DOI:https://doi.org/10.1038/sj.onc.1203922.
- Pulciani S, Santos E, Lauver AV, et al. Oncogenes in solid human tumours. Nat. 1982;300(5892):539–542.
- Créancier L, Vandenberghe I, Gomes B, et al. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma. Cancer Lett. 2015 Aug;365(1):107–111. DOI:https://doi.org/10.1016/j.canlet.2015.05.013.
- Pietrantonio F, Di Nicolantonio F, Schrock AB, et al. ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer. JNCI J Natl Cancer Inst. 2017 Dec 1;109(12). DOI:https://doi.org/10.1093/jnci/djx089.
- Cocco E, Benhamida J, Middha S, et al. Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF/KRAS are enriched for targetable kinase fusions. Cancer Res. 2019 Mar;79(6):1047–1053. DOI:https://doi.org/10.1158/0008-5472.CAN-18-3126.
- Sartore-Bianchi A, Ardini E, Bosotti R, et al. Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer. JNCI J Natl Cancer Inst. 2016 Jan;108(1). DOI:https://doi.org/10.1093/jnci/djv306.
- Drilon A, Siena S, Ou S-HI, et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017 Apr;7(4):400–409. DOI:https://doi.org/10.1158/2159-8290.CD-16-1237.
- Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK fusion–positive cancers in adults and children . N Engl J Med. 2018 Feb;378(8):731–739. DOI:https://doi.org/10.1056/NEJMoa1714448.
- Cocco E, Schram AM, Kulick A, et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nat Med. 2019 Sep;25(9):1422–1427. DOI:https://doi.org/10.1038/s41591-019-0542-z.
- Pietrantonio F, Di Nicolantonio F, Schrock AB, et al. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann Oncol. 2018 Jun;29(6):1394–1401. DOI:https://doi.org/10.1093/annonc/mdy090.
- Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma . N Engl J Med. 2005 Mar;352(10):997–1003. DOI:https://doi.org/10.1056/NEJMoa043331.
- Li Y, Lyu Z, Zhao L, et al. Prognostic value of MGMT methylation in colorectal cancer: a meta-analysis and literature review. Tumour Biol. 2015 Jan;36(3):1595–1601. DOI:https://doi.org/10.1007/s13277-014-2752-9.
- Nature P. Signatures of mutational processes in human cancer Europe PMC funders group. 2013;500(7463):415–421. DOI:https://doi.org/10.1038/nature12477.
- Pietrantonio F, Morano F, Lonardi S, et al. 383O - MAYA trial: temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS) MGMT silenced metastatic colorectal cancer (mCRC). Ann Oncol. 2021;32(suppl_5):S530–82.
- Tie J, Cohen JD, Lo SN, et al. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: individual patient pooled analysis of three cohort studies. Int J Cancer. 2021 Feb 15;148(4):1014–1026.
- Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021 Oct;27(20):5586–5594. DOI:https://doi.org/10.1158/1078-0432.CCR-21-0410.
- Tan CRC, Zhou L, El-Deiry WS. Circulating tumor cells versus circulating tumor DNA in colorectal cancer: pros and cons. Curr Colorectal Cancer Rep. 2016 Jun 7;12(3):151–161. DOI:https://doi.org/10.1007/s11888-016-0320-y.
- Zarkavelis G. Current and future biomarkers in colorectal cancer. Ann Gastroenterol. 2017;30(6):613–621.
- Boussios S, Ozturk M, Moschetta M, et al. The developing story of predictive biomarkers in colorectal cancer. J Pers Med. 2019 Feb 7:9(1):12. DOI:https://doi.org/10.3390/jpm9010012.
- Toiyama Y, Takahashi M, Hur K, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. JNCI J Natl Cancer Inst. 2013 Jun 19:105(12):849–859. DOI:https://doi.org/10.1093/jnci/djt101.
- Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol. 2020;17(1):11–32.